Shopping Cart
- Remove All
![TargetMol](https://www.targetmol.com/storage/error/oops.webp)
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $135 | In Stock | |
5 mg | $289 | In Stock | |
10 mg | $455 | In Stock | |
25 mg | $753 | In Stock | |
50 mg | $1,060 | In Stock | |
100 mg | $1,430 | In Stock | |
1 mL x 10 mM (in DMSO) | $295 | In Stock |
Description | HC-070 is a TRPC5 and TRPC4 antagonist (IC50 = 9.3 nM and 46 nM). |
Targets&IC50 | TRPC5 (human):9.3 nM, TRPC4 (human):46 nM |
In vitro | HC-070 inhibits hTRPC5 currents activated via muscarinic type 1 (IC50 = 2.0 nM) and suppresses hTRPC4 currents via muscarinic type 2 (IC50 = 0.49 nM). In whole-cell manual patch clamp, HC-070 inhibits lanthanum-activated hTRPC5-, mTRPC5-, rTRPC5-mediated currents (IC50s of 0.52 nM, 0.55 nM, and 0.32 nM). In the amygdala slices, HC-070 (20 nM) decreases CCK-4-evoked neuronal activity. HC-070 weakly inhibits TRPC3 (IC50 = 1 μM) and blocks M2R-activated human TRPC1/TRPC4 channels (IC50 = 1.3 nM) and La3+- and M1R-activated human TRPC1/5 channels (IC50 = 1.4 nM and 4.4 nM)[1]. |
In vivo | HC-070 (1 mg/kg) reduces the increased capacity for fear memory in mice subjected to chronic social stress on days 1-15. HC-070 (1 mg/kg, p.o.) affects mice with increased CCK-4-evoked anxiety. HC-070 (0.3-3 mg/kg, p.o.) causes a reduction of anxiety in a standard EPM. HC-070 (0.3-10 mg/kg, p.o.) reduces the time of immobility in a tail suspension test without impacting locomotor activity in mice. HC-070 (1-10 mg/kg, p.o.) reduces marble-burying behavior[1]. |
Alias | HC 070 |
Molecular Weight | 475.32 |
Formula | C22H20Cl2N4O4 |
Cas No. | 1628291-95-1 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 50 mg/mL (105.2 mM) | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.